Skip to Content
Search Menu
June 2.-6. 2023

We are covering ASCO 2023 | American Society of Clinical Oncology

Stay tuned

News from ASCO 2023

Oluf Dimitri Røe

Can we predict bladder cancer using the HUNT model?

/ Oluf Dimitri Røe
Bladder cancerASCO23 Play the Video
Stine Bakkensen Bruun

Circulating methylated-HOXA9 tumor DNA as a biomarker in recurrent breast cancer

/ Stine Bakkensen Bruun
Breast cancerASCO23 Play the Video
Lars Henrik Jensen

Neoadjuvant chemotherapy for locally advanced colon cancer does not change OS

/ Lars Henrik Jensen
Bowel cancerASCO23 Play the Video

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
MelanomaASCO23

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
Lung cancerASCO23

Adjuvant pembrolizumab continue to demonstrate significant improvements for patients with stage IIB/IIC melanoma

/ BestPractice Nordic
MelanomaASCO23

Prolonged Progression-Free Survival in Patients with Advanced Ovarian Cancer

/ BestPractice Nordic
Gynecological cancerASCO23

Pan tumor study – Effectively Treatment for HER2-Expressing Cancers Regardless of Tumor Location

/ BestPractice Nordic
CancerASCO23HER2
Sagar Lonial

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Sagar Lonial
CAR-TMyeloomaASCO23EHA23 Play the Video
Bjørn H Grønberg

5-years data: High-dose thoracic radiotherapy increase OS significant for patients with limited stage of small-cell lung cancer

/ Bjørn Henning Grønberg
Lung cancerASCO23 Play the Video

News from ASCO 2022

Martin Hutchings

Promising Findings for R/R Large B-cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

/ Martin Hutchings
LymphomaASCO22EHA23 Play the Video
Jeanne Tie

The randomized DYNAMIC Trial: ctDNA-guided approach towards adjuvant chemotherapy

/ Jeanne Tie
Colorectal cancerASCO22 Play the Video
David Cella, Dr

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

/ David Cella
Kidney cancerASCO22 Play the Video

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
CancerASCO22

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
LymphomaASCO22

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
Kidney cancerASCO22

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
Skin cancerASCO22

Don’t miss out on the latest news and findings within the field of hematology

Register and receive the newest articles, MEDtalk videos and magazines directly in your email.

Sign up

ASCO 2021

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

/ Ghassan Abou-Alfa
CancerASCO21 Play the Video

First-line treatment with relatinib + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma

/ Evan J. Lipson
ASCO21Melanoma Play the Video

Significantly improved pathological complete response with nivolumab + chemotherapy in NSCLC

/ Jonathan Spicer
ASCO21NSCLC Play the Video
Woman with cancer looking at x-ray

Neoadjuvant nivolumab + chemotherapy improved pathological complete response rate regardless the stage of NSCLC

/ BestPractice Nordic
ASCO21Lung cancer
Man at the doctor

Positive results presented by the VISION trial

/ BestPractice Nordic
Prostate cancerASCO21
Self Diagnosis Of Early Breast Cancer

Results of OlympiA are practice changing in treatment of breast cancer

/ BestPractice Nordic
Breast cancerASCO21

Promising results for adjuvant pembrolizumab therapy in high-risk kidney cancer

  • / BestPractice Nordic

MEDtalk ASCO 2020

ASCO20: Key takeways from ASCO20 Virtual in prostate cancer

/ Eric J. Small
Prostate cancerASCO20 Play the Video

ASCO20: Patients with non metastatic castration resistant prostate cancer

/ Eric J. Small
Prostate cancerASCO20 Play the Video

ASCO20: Significant improvement in survival for patients with stage IV/recurrent NSCLC

/ Martin Reck
ASCO20NSCLC Play the Video

Abstracts ja artikkelit ASCO 2020

Ensilinjan täsmähoito tuottaa ilahduttavia tuloksia ALK-positiivisen NSCLC:n hoidossa

/ Peter Meldgaard
ASCO20NSCLC

The SPARTAN study – the treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
Prostate cancerASCO20

Promising data for patients with inoperable, locally advanced stage III non-small cell lung cancer

ASCO20Lung cancer

Pembrolizumab in first-line therapy improves survival independent of PD-L1 expression and brain metastases in patients with NSCLC

ASCO20NSCLC

Adjuvant treatment with osimertinib in patients with stage IB-IIIA EGFR-positive NSCLC after complete tumor resection reduces the risk of relapse and death by 83%

ASCO20NSCLC

Only few patients have non-metastatic castration-resistant prostate cancer after PET scan

Prostate cancerASCO20
Mere

Lisää onkologian ja hematologian alalta

Lung Cancer

Will atezolizumab be a new standard for adjuvant treatment of NSCLC patients?

/ BestPractice Nordic
ASCO21Lung cancer
Doctor looking at lung patient's x-ray

Correlation between incidence of immune-related adverse events on atezolizumab and survival outcome

/ BestPractice Nordic
ASCO21Lung cancer

Clinical benefit of nivolumab plus cabozantinib 1st line advanced renal cell carcinoma across subgroups

/ BestPractice Nordic
ASCO21Kidney cancer

Updated data from CheckMate 9LA in advanced NSCLC show continuing benefit

/ BestPractice Nordic
ASCO21NSCLC

Choice of chemotherapy is important in 1L treatment with immunotherapy for triple-negative breast cancer

Breast cancerESMO20

ASCO20: Can you describe what characterizes the group of patients with non-metastatic castration-resistant prostate cancer?

/ Eric J. Small
Prostate cancerASCO20 Play the Video

ASCO20: Why has non-metastatic castration-resistant prostate cancer become interesting?

/ Eric Small
Prostate cancerASCO20 Play the Video

ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

/ Eric J. Small
Prostate cancerASCO20 Play the Video
Load more

Back to top